#Taiwan #Taipei #Immunotherapy #Bloomberg #HanchorBio

HanchorBio's Strategic Collaboration with Bloomberg

In a growing trend to integrate intelligent data strategies within the biopharmaceutical sector, HanchorBio, Inc. has made a significant leap by selecting Bloomberg as its collaborator to boost strategic intelligence in drug development. This partnership aims to enhance HanchorBio's capabilities across various critical areas including portfolio planning, pipeline development, and competitive monitoring.

HanchorBio, recognized for its innovative approach to developing next-generation immunotherapies, is leveraging Bloomberg’s robust data and research resources, especially through the Bloomberg Terminal. This platform provides access to Bloomberg Intelligence's Disease dashboard, which will arm HanchorBio with valuable insights into the evolving landscapes of biopharma, cutting-edge science, competitive strategies, and market dynamics associated with both public and private companies.

The need for such intelligence in drug development processes has long been recognized by HanchorBio. However, the company emphasizes that their journey toward utilizing intelligence effectively began much earlier in their operations. The recent development of HCB101, an impressive SIRPα–IgG4 Fc fusion protein, illustrates their commitment to this ethos. HanchorBio utilized advanced methodologies such as AI-guided structural engineering alongside traditional phage-display libraries to develop this product. By rigorously screening for high-affinity tumor binders and minimizing normal cell interactions, HanchorBio has showcased how a thorough understanding of molecule design underpins their strategic vision.

Scott Liu, PhD, Founder and CEO of HanchorBio, stated, "From the beginning, we recognized that biotechnology innovation hinges not only on scientific creativity but also on making informed decisions amidst growing complexities. The development of HCB101 epitomized this principle through thoughtful scientific design. Our aim now extends that philosophy beyond initial discovery into refining how we prioritize our programs and developing a framework for HanchorBio’s sustainable growth on a global scale."

HanchorBio perceives the integration of Bloomberg's insights as a way to fortify their decision-making process throughout the drug development lifecycle—starting from scientific design and clinical experimentation to regulatory execution and market strategies. Alvin Luk, PhD, Chief Medical Officer of HanchorBio, emphasized the interconnectedness of clinical development, medical sciences, and strategic execution in today's rapidly evolving biopharma landscape. "Innovation transcends mere scientific breakthroughs. It's about maintaining robust connections between various facets of drug development to enhance overall outcomes for patients," he added.

In today’s fast-paced market environment, high-quality intelligence about competitive and market dynamics has become essential for creating partnership strategies and engaging with capital markets effectively. HanchorBio's Chief Business Officer, Yuehua Cong, PhD, stressed how access to Bloomberg's data can enrich their understanding of pipeline activities, licensing tendencies, investor behaviors, and broader industry trends. This position enhances HanchorBio's ability to identify promising opportunities, judiciously assess risks, and expedite advancements in targeted biopharmaceutical therapies.

In conclusion, HanchorBio’s proactive step in adopting a data-driven approach exemplifies how strategic partnerships can fortify drug development efforts. With Bloomberg by its side, HanchorBio is poised to reinforce its position in the highly competitive global biopharmaceutical arena while striving to deliver groundbreaking therapies that address widespread medical needs.

About HanchorBio

Headquartered in Taipei with satellite offices in Shanghai and San Francisco, HanchorBio (TPEx: 7827) is dedicated to revolutionizing treatment for immuno-oncology and immune-related conditions. Their proprietary Fc-based designer biologics (FBDB™) platform is designed to create multifunctional biologics that effectively activate both innate and adaptive immune responses, aiming to tackle the limitations posed by current anti-PD1/L1 therapies. HanchorBio’s innovations are underpinned by substantial real-world data demonstrating efficacy across various tumor models, propelling the company towards addressing significant unmet medical needs in the biopharmaceutical industry. For additional information, please visit HanchorBio's official website.